Lutetium Lu-177 dotatate
FDA-approved Lu-177 DOTATATE radioligand therapy (Lutathera).
What it's for
FDA-approved Lu-177 DOTATATE radioligand therapy (Lutathera).
What it's for
Lutetium Lu-177 dotatate is a therapeutic radiopharmaceutical linking Lu-177 to the somatostatin-analog peptide DOTA-TATE. It treats somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors in adults after appropriate selection.
What it does for the body
It treats somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors in adults after appropriate selection. People often hear about it through clinics, forums, or news — this guide sticks to what published research and regulators actually support.
What it targets
SSTR2 binding delivers beta-emitting Lu-177 radiation preferentially to receptor-positive tumor cells (peptide receptors (lock-and-key landing spots on cells) radionuclide therapy). Researchers map these ideas in cells and animals first; human proof has to clear a higher bar.
Research context
Bottom line for readers: Lutetium Lu-177 dotatate has a defined FDA-approved story. Use the citations tab to open labels and trial registries, and treat anything beyond the label as unverified.
Studied for (literature interest)
- Digestive research interest (educational tag)
Cautions (educational)
- Educational only — not medical advice.
- DrPep does not offer medical consultations, dosing guidance, suppliers, or peptide sales.
Citations / starters
- FDA search: Lutetium Lu-177 dotatate — FDA.gov search
- ClinicalTrials.gov search: Lutetium Lu-177 dotatate — U.S. clinical trials registry
- Drugs@FDA search: Lutetium Lu-177 dotatate — FDA drug database (if approved)
- PubMed search: Lutetium Lu-177 dotatate — NCBI PubMed
- PubMed Central search: Lutetium Lu-177 dotatate — NCBI PMC